By Rob Scott
MEDFORD, Ore. — The FDA has announced that a new treatment is available for those suffering from COPD. The current staff at the Sun Stone Medical Research helped document trial runs of the newly approved Tudorza Pressair. A patient who NewsWatch12’s Rob Scott spoke with was a part of that study and say it will be her treatment of choice for her COPD.
Pamela York was diagnosed with COPD five years ago, and with fall just around the corner, the FDA has announced that a new treatment for COPD called Tudorza Pressair has been cleared for public use. But the new medicine isn’t new to York.
“It helped me breath a lot easier. I don’t seem to have the bronchitis, severe bronchitis, that I did have,” York describes. She was a part of a trial for the new drug that took place at different sites around the country including right here in Medford.
“Many times people get short of breath and they feel like they just have to live with it and this drug and others like it can really make a difference and allow people to breath more easily,” Dr. Chris Alftine. Dr. Alftine helped oversee the trials that went on in Medford and says he saw good results.
“So many of the medicines we are prescribing these days have a tendency to cause side effects and this is one we can be relatively sure won’t cause much trouble,” Dr. Alftine says.
Pamela York says it was the first study she participated in and that it wasn’t much work at all.
“Keep a log of how you’re doing and taking the medication at home,” she says. “It was really a good study.”
More than 12 million people are currently diagnosed with COPD and it is the third leading cause of death in the United States according to the National Heart Lung and Blood Institute. The newly approved Tudorza Pressair is expected to be available later this year.